Drug addiction results in part from the distortion of dopamine-controlled plasticity.
Introduction
A variety of substances naturally produced by plants (cocaine, morphine, cannabinoids, nicotine) or synthesized by humans with various degrees of sophistication (ethanol, heroin, amphetamine) trigger a peculiar behavior of recurrent consumption, in humans as in experimental animals. This response can become compulsive and lead to a pathological state called addiction, with its well known deleterious consequences for health and society.
Addiction is a chronic disease with a high risk of relapse even after a long time of withdrawal, revealing stable brain alterations. A chief aspect of addiction is related to the distortion of reward mechanisms dependent on dopamine (DA) [1] [2] [3] . Thus, drugs of abuse are the source of a major medical problem and, at the same time, the Ariane's thread that may lead neuroscientists through the maze of a major learning mechanism.
Drugs of abuse enhance extracellular DA levels in the forebrain, especially in the nucleus accumbens (NAcc ) where they control corticostriatal glutamate transmission [1] [2] [3] . A critical question is the nature of the signaling mechanisms activated by DA in striatal and other target neurons that trigger the long-lasting alterations responsible for the behavioral effects of drugs of abuse. This question is not only theoretical but may have clinical implications, since deciphering these mechanisms may lead to novel strategies to modify, or even reverse, some of the seemingly irreversible consequences of addiction. Several signaling pathways have been implicated in the actions of DA. Here, we focus on the role of the extracellular signal-regulated kinase (ERK) pathway, one of the highly conserved mitogenactivated protein kinase (MAP-kinase) modules.
The ERK pathway
MAP-kinases modules comprise 3 classes of enzymes that act in a cascade of activatory phosphorylation: the upstream kinases, or MAP-kinase/ERK-kinase-kinases (MEKK), phosphorylate and activate the MAP-kinase/ERK-kinases (MEK). MEKs are dual specificity kinases, which trigger the activation MAP-kinases by phosphorylating a threonine and a tyrosine in their activation loop. Specificity in the signaling between these modules is achieved by protein-protein interactions and scaffolding molecules [4] . The ERK kinase family (ERK1-8) is characterized by a Thr-Glu-Tyr motif in the activation loop.
Phosphorylation of both the Thr and Tyr residues in this motif is required for ERK activation.
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This double phosphorylation is easily detected by specific antibodies, and in many studies is taken as a reliable index of the activity of ERKs. ERK1-2 is of paramount importance in the control of cell growth and differentiation, and is also involved in neuronal plasticity [5, 6] . The ERK1/2 module is turned on by tyrosine kinase and G protein-coupled receptors through the generation of GTP-bound forms of small G proteins of the Ras family. These small G proteins activate MEKKs of the Raf family (mostly Raf-1 and B-Raf in the brain) [4] , which phosphorylate and activate MEK1/2, which phosphorylate and activate ERK1/2. ERK1/2 phosphorylate numerous substrates at (Ser/Thr)-Pro sites in all cell compartments, including the nucleus where they play a key role in gene regulation. Among the other ERKs that have been studied in some details, ERK5 is also highly expressed in brain and is involved in cortical progenitor differentiation [7] . Since the role(s) of ERK3-8 in adult brain are not yet characterized this review focuses on ERK1/2.
Drugs of abuse activate ERK1/2 in a subset of neurons in brain reward circuits
Activation of ERK1/2 in response to addictive drugs was first reported in the ventral tegmental area (VTA) after a 5-day exposure of rats to morphine or cocaine [8] . Subsequently, acute treatment of mice with cocaine was shown to induce a rapid and transient increase in ERK phosphorylation in the NAcc [9] , an effect reproduced with other drugs of abuse including ∆9-tetrahydrocannabinol (THC), D-amphetamine, 3,4-methylene-dioxymethamphetamine (MDMA), morphine, and nicotine [10] [11] [12] [13] . Brain mapping after acute treatment with drugs of abuse and other psychoactive compounds revealed a common regional pattern of ERK1/2 activation, characteristic of abused drugs, including nucleus accumbens, lateral bed nucleus of stria terminalis, central amygdala and deep layers of the prefrontal cortex [12] (Table 1 ).
In the regions listed above, the activation of ERK1/2 by drugs of abuse is blocked by a D 1 DA receptor (D 1 -R) antagonist [9, 11, 12] . In the striatum, ERK1/2 activation in response to D-amphetamine occurs in a subset of GABAergic medium spiny neurons (MSNs) expressing
. Selective stimulation of D 1 -R in vivo has a weaker effect on ERK activation [15, 16] . In fact ERK activation by drugs involves also glutamate since responses to cocaine, D-amphetamine or THC are prevented by NMDA antagonists [9, 11, 14] or, in the case of amphetamine, by group I metabotropic glutamate receptor (mGluR) [13] . These observations have important functional implications, since they imply that the ERK pathway behaves as a coincidence detector of the activation of DA and glutamate pathways [14] . In striatal neurons in culture, D 1 -R stimulation increases weakly ERK1/2 phosphorylation, whereas agonists of glutamate ionotropic and group I metabotropic receptors induce a stronger activation [17, 18] .
Activation of DA and glutamate receptors seems to potentiate each others [17, 18] . Other receptors such as DA D 2 receptors [9] and cannabinoid CB 1 receptors (Corbillé et al in preparation) appear to play a role in the activation of ERK1/2 by drugs of abuse, although this role is likely to be indirect.
The precise mechanisms of activation of ERK1/2 in striatal neurons in response to drugs of abuse are still incompletely understood ( Fig. 1 ). Several possible pathways coupling NMDA receptors activation to ERK1/2 phosphorylation through Ca 2+ influx have been proposed in other systems (see [5, 6] ), but their role in MSNs remains to be clarified. On the other hand the regulation of ERK1/2 by D 1 -R is better characterized and involves dopamineand cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) [14] ( Fig. 1 ). Although other links with D 1 receptors may exist, the regulation of protein phosphatases through DARPP-32 appears critical for the activation of ERK1/2 in the striatum.
Role of ERK in psychomotor sensitization and rewarding effects of drugs
The major tools used to address the role of ERK1/2 are inhibitors of MEK, either microinjected in specific brain regions (PD98059 and U0126) or, in the case of SL327 which crosses the blood brain barrier, administered intraperitoneally. The specificity of microinjected inhibitors is difficult to assess since their concentrations in the vicinity of the injection point is likely to exceed those recommended in vitro. On the other hand, the site of action of SL327 injected at the periphery cannot be determined. Therefore, both approaches have limitations and cautious interpretation of the results is advisable. This is further underscored by the fact that the spectrum of action of these compounds is not limited to the ERK1/2 pathway [7] .
At a dose (30 mg/kg) which inhibited by >80% ERK phosphorylation in the striatum, SL327 did not alter mouse spontaneous activity or acute locomotor responses to cocaine or Damphetamine [14, 19] . Thus, ERK1/2 activation seems to play little role, if any, in the locomotor effects of the first injection of drug. By contrast, SL327 prevented the induction of locomotor sensitization by a single or repeated injections of cocaine or D-amphetamine [14, 19, 20] . SL327 also prevented the acquisition of a conditioned locomotor response triggered by cocaine or D-amphetamine-paired context [19] . Importantly, blockade of ERK1/2 activation did not prevent the expression of previously acquired sensitization [19] .
The site of action of SL327 may include the VTA since local inhibition of MEK abolished the initiation of sensitization to cocaine without affecting acute responses [21] . However, since the activation of ERK1/2 by cocaine is much less robust in the VTA than in other brain structures [12] , ERK activation in the accumbens and/or cortex may also participate in the induction of psychomotor sensitization.
The induction of conditioned place preference (CPP), usually presented as an index of the "rewarding effects" of drugs, also requires ERK1/2 activation. Blockade of ERK1/2 activation, by systemic administration of SL327 and/or local injection of MEK inhibitors in the NAcc during the training sessions prevented the induction of conditioned place preference by cocaine, D-amphetamine, MDMA or THC [9] [10] [11] 22 ].
Role of ERK1/2 in drug-conditioned responses and in their "reconsolidation"
Sensory stimuli by themselves unable to activate ERK1/2, can do so when they have been associated repeatedly with drugs. After acquisition of cocaine self-administration, the presentation of drug-associated cues increases ERK1/2 phosphorylation in central amygdala after one month of withdrawal [23] . In animals trained for CPP with cocaine or methamphetamine, exposure to the test apparatus is sufficient to activate ERK1/2 in the nucleus accumbens, caudate-putamen and prefrontal cortex [24] [25] [26] . Whether these activations of ERK1/2 by environmental cues are mediated by the same molecular pathways as those initially triggered by drugs, is not known.
Interestingly ERK1/2 seems to be important for the expression of drug conditioned responses. Local injection of MEK inhibitors in the NAcc abolished the expression of CPP to cocaine and methamphetamine [24, 25] . Similarly, injection of U0126 in the central amygdala prevented cocaine seeking in rats previously trained to self-administer this drug [23]. These observations are very interesting since they suggest a more important role of ERK1/2 in the expression of the conditioned behavioral response than in the response to the initial drug injection.
In various learning models, including object recognition and fear conditioning, reexposure to the sensory cues leads to memory reconsolidation. During this phase memories are sensitive to protein synthesis and MEK inhibitors [27, 28] . Two studies have implicated ERK1/2 in the reconsolidation of CPP induced by cocaine or morphine [25, 26] . Local injection of MEK inhibitors in the nucleus accumbens, before or immediately after retrieval of conditioned response disrupted cocaine CPP tested 1 or 14 days later [25] . Systemic injection of SL327, or of a protein synthesis inhibitor, erased previously acquired morphine or cocaine CPP [26]. However, SL327 was efficient only if administered just before a supplemental conditioning session with the drug, but not before a simple exposure to the conditioned environment. The same requirement for re-exposure to both drug and context was also observed in a study using protein synthesis inhibitors to erase morphine-conditioned responses [29] . Additional work is required to determine whether these discrepancies are due to differences in the experimental protocols. The important common finding is that inhibition of the ERK1/2 pathway during the "reconsolidation" phase eliminates the conditioned response to drugs. Similar results have been obtained by inhibition of Zif268 (also known as Krox24 or NGFI-A) expression in the amygdala [30], where its expression is also SL327sensitive [31] . These studies suggest that established conditioning, which contributes to the high rate of relapse in addicts, could be accessible to therapeutic agents. It will be important to determine whether a strong and prolonged conditioning is also liable to pharmacological erasure. As could be expected, our preliminary results indicate that following a prolonged conditioning procedure, CPP becomes more resistant to erasure by a MEK inhibitor.
Therefore, further experiments are required to determine to which extent pharmacological treatments, combined or not with appropriate behavioral stimuli, can reverse strong conditioning.
Molecular targets of ERK
The evidence summarized above strongly supports the role of ERK1/2 in the acquisition of long lasting behavioral effects of drugs of abuse, and, possibly, in their expression. It is clearly of great interest to identify the substrates of ERK1/2 which are important in either case.
Phosphorylated ERK1/2 is detected in both dendrites and perikarya of striatal neurons and rapidly accumulates in the nucleus. The rapid time scale of these responses [24, 25] suggests that ERK influences conditioned responses via mechanisms other than transcription. A possible target could be the voltage-dependent K + channel, Kv4.2, which is an important ERK1/2 substrate in the hippocampus [6] . Beyond these very rapid effects, ERK1/2 signaling plays a major role in regulating activity-related spine dynamics [32, 33] , glutamate receptors insertion at synapses [34, 35] , and dendritic protein synthesis [34, 35] . All these effects of ERK1/2 have been identified in the hippocampus and examining their possible role in other brain regions more directly related to addiction is an interesting area for future research.
Drug administration triggers a complex transcriptional program in the striatum that depends on the combined stimulation of D 1 and NMDA receptors [36] . Gene expression is thought to be essential for the long-term behavioral changes induced by drugs. Gene transcription is markedly inhibited by pharmacological inhibition of MEK [9] [10] [11] 20, [37] [38] [39] . . Since Zif268 is itself a transcription factor, the identification of its targets will be important for characterizing long term effects of drugs of abuse. In this respect it is interesting to note that p35, the regulatory subunit of Cdk5, a protein important in the effects of cocaine (see [40] ), is induced by ERK1/2 through Zif268 [41]. Interestingly glucocorticoids, which play an essential role in the regulation of drug responses by stress, upregulate the ERK/Zif268 pathway [42] .
Opposing roles of ERK1 and ERK2
Although they have 90% sequence identity, ERK 1 and ERK2 appear to have distinct, even sometimes opposite functional effects [43, 44] . Thus, ERK1 can inhibit ERK2 signaling, possibly by competition for phosphorylation by MEK. Drug-induced phosphorylation of ERK2 appears much stronger than ERK1 (e.g. [14] ). In ERK1 knockout mice, which are viable and fertile, CPP evoked by morphine or cocaine and psychomotor sensitization to cocaine were enhanced [20, 44] . Cocaine-induced gene transcription was also increased [20] .
Assuming that the numerous effects of MEK inhibitors reported above are due to the inhibition of ERK1 and ERK2, these results indicate that ERK2 is the isoform important for the behavioral effects of drugs of abuse.
Conclusion: possible functional role of ERK2 in the effects of drugs of abuse and beyond
The evidence summarized above underlines the key role of the ERK2 pathway in long-lasting effects of drugs of abuse. In striatal MSNs its activation requires both dopamine and glutamate inputs, suggesting that it functions as a logical AND gate (Fig. 3) . This gate will detect the coincidence of environmental cues (glutamate) and positive reward prediction error signals (dopamine). Evidence suggests that when activated the ERK2 pathway puts the neuron in a plasticity-permissive state, both at the level of dendrites and by regulating nuclear transcription (see Fig. 3 ). Although, it is likely that evolution has selected several molecular devices with similar properties to ensure an optimal signal processing in neuronal systems critical for survival, the ERK2 pathway is possibly the first to be clearly identified as such.
Even though better characterized in the striatum, the same model might apply to other regions involved in the effects of drugs of abuse including amygdala and prefrontal cortex. Future work will test these hypotheses and determine how much of these mechanisms uncovered in the context of drugs of abuse is also relevant for learning controlled by natural rewards. This paper shows that exposure of rats previously conditioned for cocaine CPP to the conditioned cues activates the ERK pathway in the accumbens core. Moreover, using microinjections of MEK inhibitors it provides evidence that blocking this pathway prevents the expression of CPP 1 or 14 days later. This work suggests that drug-induced conditioning undergoes a reconsolidation process, activated by contextual cues, similar to other types of memories. Other studies (see Refs. 26, 29) have found similar results using inhibitors of MEK or protein synthesis inhibitors injected at the periphery. An interesting difference is that in the latter studies, exposure to the context alone was not sufficient for the pharmacological disruption of the CPP, it also required re-exposure to the drug. This could be due to a lack of specificity of microinjected drugs or to differences in the experimental protocols. Using non-neuronal cell systems this paper shows that ERK1 can exert effects opposite to those of ERK2 and that the equilibrium between the two isoforms probably controls the The number of P-ERK1/2-positive cells was measured 10 min after the injection of cocaine (20 mg/kg) or 20 min after the injection of nicotine (0.4 mg/kg), morphine (5 mg/kg), or THC (1mg/kg). Significant increases, as compared to vehicle administration: + (<3-fold) and ++ (≥3-fold). Drugs of abuse were the only substances to activate ERK1/2 in all the brain regions indicated in bold and italics. These increases were prevented in SCH23390-pretreated mice.
The NAcc was the only region in which P-ERK1/2 was not increased by non-addictive drugs.
Data from Ref. [12] . BNST: bed nucleus stria terminalis. 
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